Relay Therapeutics officer sells 50,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relay Therapeutics, Inc. officer Peter Rahmer reported a sale of 50,000 shares of common stock on June 30, 2026 at a weighted average price of $19.09 per share, executed in multiple trades pursuant to a Rule 10b5-1 trading plan adopted on October 31, 2025. He also acquired 3,056 shares at $6.95 per share. After these transactions he directly holds 228,913 shares, including 9,153 shares underlying restricted stock units.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 50,000 | $19.09 | $955K |
| Grant/Award | Common Stock | 3,056 | $6.95 | $21K |
Footnotes (5)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $18.66 to $19.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3. Includes 9,153 shares underlying restricted stock units.
- F4. The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
- F5. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on January 2, 2026.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
restricted stock units financial
Employee Stock Purchase Plan financial
Rule 16b-3(d) regulatory
Rule 16b-3(c) regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Peter Rahmer report for RLAY on June 30, 2026?
Was the June 30, 2026 RLAY stock sale made under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.